<DOC>
	<DOCNO>NCT01309113</DOCNO>
	<brief_summary>Prospective , double-blind , placebo-controlled , 3 parallel group , multi-center study 180 patient cyclic mastodynia premenstrual syndrome . 225 patient screen achieve 180 patient eligible randomisation , 60 treatment group , 150 expect complete study per protocol . Study objective : Identification optimal dosage VAC BNO 1095 ( product name ) film coat tablet treatment cyclic mastodynia premenstrual syndrome . To prove efficacy VAC BNO 1095 film coat tablet treatment cyclic mastodynia . Dose regimen : Group 1 : VAC BNO 1095 1x10 mg : 1 tablet verum morning , 1 placebo tablet even Group 2 : VAC BNO 1095 2x10 mg : 1 tablet verum morning , 1 tablet verum even Group 3 : Placebo : 1 tablet placebo morning , 1 tablet placebo even The study consist 2-cycle run-in period , follow 3 cycle treatment . After first screen visit schedule end first second run-in cycle , first , second third treatment cycle , respectively . Visits perform menses day 3 ( -1+3 day ) , i.e . 2 day day 1 menstruation number n , exception first screen visit perform time prior first run-in cycle . Subsequently time first study visit onset first run-in cycle menses T shall add overall study duration . In case next menstruation commence expect , patient contact investigator immediately order schedule new appointment , approximately actual day 3 menses .</brief_summary>
	<brief_title>Dose-dependent Effects VAC BNO 1095 Cyclic Mastodynia Premenstrual Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Premenstrual Syndrome</mesh_term>
	<mesh_term>Mastodynia</mesh_term>
	<criteria>Females age 18 45 sign Informed Consent Form ( ICF ) screen visit S2 ( screen visit 2 ) late . Subject history cyclic mastodynia premenstrual syndrome Stable cycle duration 25 35 day past 6 month screen visit S2 . At screen visit S2 subject reporting least one physical premenstrual syndrome symptom rat moderate severe ( lead symptom require treatment ) one psychic symptom late luteal phase precede cycle , use Calendar Premenstrual Experiences ( COPE ) symptom list At screen visit S2 subject reporting symptom total score least 15 late luteal phase precede cycle , use Calendar Premenstrual Experiences ( COPE ) symptom list In runin cycle : Visual analog scale great equal 50 mm least one day late luteal phase Cyclic course mastodynia , i.e . visual analog scale mid follicular phase ( maximum value 5 daily recording ) less 75 % visual analog scale late luteal phase ( maximum value 5 daily recording ) Premenstrual syndrome sum score result Calendar Premenstrual Experiences ( COPE ) must 20 late luteal phase ( average daily recording document day 5 1 ) At least one physical premenstrual syndrome symptom must rat moderate severe least one day late luteal phase , one psychic symptom present Premenstrual syndrome sum score result Calendar Premenstrual Experiences ( COPE ) must exceed 10 day 4 menstruation Premenstrual syndrome sum score result Calendar Premenstrual Experiences ( COPE ) must exceed 8 mid follicular phase ( average daily recording document day 6 10 ) Note : `` Late luteal phase '' define day 5 1 ( 5 day prior onset menses ) `` mid follicular phase '' define day 6 10 onset menses . Exclusion criterion : Pre Menstrual Dysphoric Disorder Intake follow medication treatment start ( visit S2 visit V0 ) within 6 month prior visit S2 : Any treatment mastodynia premenstrual complaint Sexual hormone , combination inhibitor Pituitary hormone inhibitor Hypothalamic hormone Neuroleptics , antidepressants Serotoninreuptakeinhibitors Prolactininhibitors prolactin stimulate preparation Non Steroidal AntiInflammatory Drugs ( NSAIDs ) analgetics include antirheumatics Spironolactone Androgens Gonadotrophin inhibitor Diuretics Danazol Psychotropic agent</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>